References
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW.
- Merritt Neurologia, t. 2, cz. XIII-XXII, red. E. D. Louis, S. A. Mayer, J. M. Noble, red. wyd. pol. W. Turaj, Wrocław, Edra Urban & Partner, 2023.
- Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, Lillehei KO. Characterization of glioblastomas in young adults. Brain Pathol. 2006 Oct;16(4):273–86. doi: 10.1111/j.1750–3639.2006.00029.x. PMID: 17107596; PMCID: PMC8095924.
- Ejma. M, Waliszewska-Prosół M, Hofman A i wsp. Rzadkie kliniczne odmiany glejaka wielopostaciowego. Postępy Hig Med Dośw 2014; 68: 316–324.
- Polivka J Jr, Polivka J, Holubec L i wsp. Advances in experinental targeted therapy and immuno-therapy for patients with glioblastoma multiforme. Anticancer Res 2017; 37: 21–23.
- You H, Geng S, Li S, Imani M, Brambilla D, Sun T, Jiang C. Recent advances in biomimetic strategies for the immunotherapy of glioblastoma. Biomaterials. 2024 Dec;311:122694. doi: 10.1016/j. biomaterials.2024.122694. Epub 2024 Jun 28. PMID: 38959533.
- Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016 Nov;18(11):1062–1071. doi: 10.1007/s12094–016–1497-x. Epub 2016 Mar 10. PMID: 26960561.
- Brown NF, Ottaviani D, Tazare J, Gregson J, Kitchen N, Brandner S, Fersht N, Mulholland P. Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers (Basel). 2022 Jun 28;14(13):3161. doi: 10.3390/cancers14133161. PMID: 35804940; PMCID: PMC9265012.